Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential sintilimab + ipilimumab N01 and chemotherapy after concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2600132455Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and ipilimumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Conversion success rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600132455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132455.